The market for Alzheimer’s disease will double to $10.4 billion by 2021, a new report from GBI Research projects. This is thanks largely to the growing incidence of the disease, particularly in developed nations. However, innovations in the drug pipeline will help drive market growth as well.
“While many of the later-stage therapies focus on common targets, the earlier stages of the pipeline do not appear to follow this trend, as they contain many first-in-class molecules with novel molecular targets within the context of Alzheimer’s disease therapeutics,” Yasser Mushtaq, author of the report, said in a statement.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
The first new approvals for Alzheimer’s disease drugs will drive growth during the forecast period, he said. Promising contenders include Merck’s verubecestat, Biogen’s aducanumab and VTV Therapeutis’ azeliragon. A number of companies are delving into the basic science of the disease these days, and are developing both small molecule and immunotherapy approaches to this neurodegenerative disease.
The market settled in at just below $5 billion in 2014. Moving forward, the major markets for growth in Alzheimer’s are the U.S., Canada, France, Germany, Italy, Spain, the UK and Japan.
